- Home
- FTHY vs AQST Comparison
FTHY vs AQST Comparison
Compare FTHY & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHY | AQST |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.6M | 529.4M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | FTHY | AQST |
|---|---|---|
| Price | $13.55 | $3.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 80.2K | ★ 2.2M |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 10.93% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | N/A | $10.08 |
| Revenue Next Year | N/A | $49.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $13.20 | $2.94 |
| 52 Week High | $14.86 | $7.55 |
Technical Indicators
Market Signals| Indicator | FTHY | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 47.99 | 34.00 |
| Support Level | $13.40 | $3.16 |
| Resistance Level | $13.78 | $4.38 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 48.08 | 10.81 |
Price Performance
Historical ComparisonAbout FTHY First Trust High Yield Opportunities 2027 Term Fund
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income. The fund invests a majority of its managed assets in high-yield debt securities of any maturity that are rated below investment grade at the time of purchase or unrated securities. Its investment portfolio comprises corporate bonds and notes, senior floating-rate loan interests, foreign corporate bonds and notes, money market funds, and other instruments across various industries.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.